Effects of Androgen Administration on Inflammation in Normal Women
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01753037|
Recruitment Status : Completed
First Posted : December 20, 2012
Last Update Posted : November 18, 2013
|Condition or disease||Intervention/treatment|
|Hyperandrogenism||Dietary Supplement: Dehydroepiandrosterone (DHEA) Other: Placebo|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||25 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Primary Purpose:||Basic Science|
|Official Title:||Effects of Oral Androgen Administration on Hyperglycemia-Induced Inflammation in Lean Reproductive-Age Women|
|Study Start Date :||December 2006|
|Primary Completion Date :||April 2010|
|Study Completion Date :||April 2010|
Active Comparator: DHEA Group
Oral administration of a capsule containing 130 mg of dehydroepiandrosterone (DHEA) for 5 days.
Dietary Supplement: Dehydroepiandrosterone (DHEA)
DHEA 130 mg administered orally for 5 days.
Placebo Comparator: Placebo Group
Oral administration of an identical capsule containing placebo for 5 days.
Placebo contained in a capsule that is identical in appearance to the one used to package DHEA for 5 days.
- Nuclear factor kappa B (NFkappaB) activation [ Time Frame: 0 and 2 hours after glucose ingestion ]White blood cell NFkappaB activation will be assessed in response to glucose ingestion before and after 5 days of DHEA or placebo administration.
- Insulin sensitivity [ Time Frame: 0 and 5 days after DHEA or placebo ]Insulin sensitivity derived from an oral glucose tolerance test (OGTT) will be assessed before and after 5 days of DHEA or placebo administration.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01753037
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Frank González, M.D.||Mayo Clinic|